Other substances

Entrectinib

A tropomyosin receptor kinases inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

Entrectinib is a selective tyrosine kinase inhibitor (tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK)). Its activity leads to cell death and inhibition of tumour cell proliferation (NCIt). It has been approved as a last line therapy for cancer types (DrugBank).

Entrectinib on PubChem
Entrectinib on Wikipedia

Marketed as

ROZLYTREK

 

Structure image - Entrectinib

CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6

Supporting references

Link Tested on Impact factor Notes Publication date
Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server
in silico 4.55

Predicted to bind a SARS-CoV-2 protein structural feature.

 Aug/11/2020
Molecular Features of Non-Selective Small Molecule Antagonists of the Bradykinin Receptors
Small molecule In silico 		in silico 4.29

Predicted to non-selectively bind bradykinin receptors, which was theorised to alleviate SARS-CoV-2-related inflammation.

 Sep/21/2020

AI-suggested references

Link Publication date
Entrectinib-A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells.
Oct/13/2020
Export (.csv)